logo
Plus   Neg
Share
Email

AstraZeneca To Sublicense Worldwide Rights To Movantik To RedHill Biopharma

British drug major AstraZeneca (AZN,AZN.L) said Tuesday it has agreed to sublicense its global rights to Movantik, a peripherally acting mu-opioid receptor antagonist indicated for the treatment of opioid-induced constipation, to RedHill Biopharma.

As part of the deal, which excludes Europe, Canada and Israel, AstraZeneca will continue to manufacture and supply Movantik to RedHill during a transition period. Earlier in 2015, AstraZeneca entered into a co-commercialisation deal with Daiichi Sankyo for Movantik in the US, which will be transferred to RedHill.

With regards to financial terms of the deal, RedHill will make an upfront payment of $52.5 million to AstraZeneca, upon closing, and a further non-contingent payment of $15 million in 2021.

Meanwhile, profit arising from the upfront payment, after taking a charge for derecognition of the associated intangible asset, and the future payment will be reported in AstraZeneca's financial statements.

The divestment is expected to be complete in the first quarter of 2020, subject to customary closing conditions and regulatory clearances. Upon completion, the deal will not impact the Company's financial guidance for 2020, Astrazenenca reported.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walt Disney Co.'s streaming service Disney+ now has 50 million paid subscribers globally, with the company achieving the milestone within five months after its U.S. launch. WeWork's parent company, We Company, said it has filed a lawsuit against Japanese conglomerate SoftBank Group Corp. for failing to consummate a $3 billion tender offer for the company's shares. After WeWork's failed attempt at an initial public offering last year, SoftBank acquired a majority stake in the office sharing company in a bailout, severing most ties with WeWork co-founder Adam Neumann. Walgreens is expanding drive-thru testing for the coronavirus to fifteen new locations in seven states across the U.S. later this week. They include Arizona, Florida, Illinois, Kentucky, Louisiana, Tennessee and Texas. The drive-thru locations are part of Walgreens' collaboration with the administration, federal health agencies, and state and local authorities to expand access to COVID-19 testing.
Follow RTT
>